ISOREA AB
About
The progression of Alzheimer’s Disease (AD) can be slowed down when detected early with available drugs! Yet there are no scalable and low-cost test for early screening available.
Alzheimer’s Disease is a terrible neurodegenerative illness that causes disability and dependency among older people globally. It contributes to approximately 60-70% of all dementia cases. According to the WHO more than 55 million people worldwide are currently living with dementia, and millions of new cases appear every year. This is estimated to triple to 152 million cases by 2050.
If Alzheimer’s Disease is detected early, the progression of the disease can be slowed down before significant damage has occurred.
In response to these challenges, ISOREA has developed a breakthrough early Alzheimer’s Disease Risk Detection Kit, which enables to detect the risk of Alzheimer’s Disease 6-10 years ahead by using an affordable and easy to roll-out blood test using two Biomarkers- the Risk Factor and the Natural Defense Strength. It has >92% sensitivity in detecting Pre-Alzheimer's stage, i.e., MCI stage.
ISOREA targets the rapidly growing (CAGR 9.4%) global Alzheimer’s Disease diagnostics market estimated to reach €21 billion by 2030, with a specific focus on AD disease screening.
What is your business/industry sector?